Weiner discloses 51,850-share, 5.07% stake in Psyence Biomedical (PBM)

Rhea-AI Filing Summary

Psyence Biomedical Ltd. Schedule 13G reports that Weiner Jeffrey David beneficially owns 51,850 common shares, representing 5.07% of the class as of 02/13/2026.

The filing shows Mr. Weiner has sole voting and dispositive power over all 51,850 shares. The filing gives the issuer address as 121 Richmond Street West, Penthouse, Suite 1300, Toronto, Ontario, Canada.

Insights

Corporate Governance Specialist

Beneficial owner crosses 5% threshold, requiring public disclosure under Section 13.

The filing documents that Weiner Jeffrey David holds 51,850 common shares, equal to 5.07% as of 02/13/2026, and reports sole voting and dispositive power. This level of ownership typically triggers enhanced disclosure obligations and public visibility for a passive stake.

Timing and intent are not stated in the excerpt; subsequent filings may disclose changes in ownership or intent. The reported address and CUSIP are provided for identification.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PSYENCE BIOMEDICAL LTD.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

74449F308

(CUSIP Number)

02/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74449F308

1

Names of Reporting Persons

Weiner Jeffrey David

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 51,850.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 51,850.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

51,850.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.07 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PSYENCE BIOMEDICAL LTD.
(b)	Address of issuer's principal executive offices: 121 RICHMOND STREET WEST PENTHOUSE, SUITE 1300, TORONTO, ONTARIO, CANADA
Item 2.
(a)	Name of person filing: Weiner Jeffrey David
(b)	Address or principal business office or, if none, residence: 1856 E Hamlin Street, Seattle, WA 98112
(c)	Citizenship: United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 74449F308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 51,850
(b)	Percent of class: 5.07 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 51,850
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 51,850
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Weiner Jeffrey David

Signature:	Weiner Jeffrey David
Name/Title:	Individual
Date:	02/18/2026

FAQ

What stake does Jeffrey David Weiner report in Psyence Biomedical (PBM)?

He reports beneficial ownership of 51,850 common shares, representing 5.07% of the class as of 02/13/2026. The filing shows sole voting and dispositive power over these shares.

What type of SEC filing did Psyence Biomedical receive for this disclosure?

The disclosure is a Schedule 13G, a beneficial ownership filing used to report passive or qualifying ownership. It lists the holder, share count, and percentage of the class on the filing date.

Does the filing indicate whether the shares are held directly or indirectly?

The filing states sole voting and dispositive power for Mr. Weiner over 51,850 shares, indicating direct control as reported; no indirect holding structure is disclosed in the excerpt.

What issuer information is shown in the filing for PBM?

The filing lists the issuer as Psyence Biomedical Ltd. with principal offices at 121 Richmond Street West, Penthouse, Suite 1300, Toronto, Ontario, Canada, and CUSIP 74449F308.

What dates appear on the filing for the ownership report?

The ownership is reported as of 02/13/2026, and the filing is signed and dated 02/18/2026 by Weiner Jeffrey David, the reporting individual.